Sitagliptin as add-on therapy in insulin deficiency: Biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 99-104

  Giampietro, Ottavio ^a   Giampietro, Chiara ^a   Della Bartola, Luca ^a   Masoni, Maria Chiara ^a   Matteucci, Elena ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Diabetes mellitus; Dipeptidyl peptidase 4inhibitors; Drug therapy combination; Metformin; Synthetic analogs of insulin; Type 1; Type 2

Indexed keywords

BIOLOGICAL MARKER; FRUCTOSAMINE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN PLUS SITAGLIPTIN; SITAGLIPTIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FRUCTOSAMINE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; WEIGHT REDUCTION;

DIABETES MELLITUS; DIPEPTIDYL-PEPTIDASE-4 INHIBITORS; DRUG THERAPY COMBINATION; METFORMIN; SYNTHETIC ANALOGS OF INSULIN; TYPE 1; TYPE 2;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; PYRAZINES; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84873970595     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S38346     Document Type: Article

References (27)

1. American Diabetes Association. Standards of medical care in diabetes 2012. Diabetes Care. 2012;35 Suppl 1:S11-S63.
2. Braga MF, Casanova A, Teoh H, et al; Diabetes Registry to Improve Vascular Events [DRIVE] Investigators. Poor achievement of guidelines recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study. Int J Clin Pract. 2012;66(5):457-464.
3. Vouri SM, Shaw RF, Waterbury NV, Egge JA, Alexander B. Prevalence of achievement of A1c, blood pressure, and cholesterol (ABC) goal in veterans with diabetes. J Manag Care Pharm. 2011;17(4):304-312.
4. Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy. 2010;30(5):463-484.
5. Phillips LK, Prins JB. Update on incretin hormones. Ann N Y Acad Sci. 2011;1243:E55-E74.
6. Matteucci E, Giampietro O. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Curr Med Chem. 2009;16(23):2943-2951.
7. Matteucci E, Giampietro O. Dipeptidyl peptidase-4 inhibition: linking chemical properties to clinical safety. Curr Med Chem. 2011;18(31):4753-4760.
8. Rizos EC, Ntzani EE, Papanas N, et al. Combination therapies of DPP4inhibitors and GLP1 analogues with insulin in type 2 diabetic patients: a systematic review. Curr Vasc Pharmacol. June 22, 2012. [Epub ahead of print.]
9. Kutoh E. Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series. J Med Case Rep. 2011;5:117.
10. Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK. Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med. 2011;28(10):1176-1181.
11. George P, McCrimmon RJ. Potential role of non-insulin adjunct therapy in type 1 diabetes. Diabet Med. July 18, 2012. [Epub ahead of print.]
12. Dhillon S. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2010;70(4):489-512.
13. Chwieduk CM. Sitagliptin/metformin fixed-dose combination in patients with type 2 diabetes mellitus. Drugs. 2011;71(3):349-361.
14. Williams-Herman D, Engel SS, Round E, et al. Safety and toler-ability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord. 2010;10:7.
15. Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care. 2010;33(7):1509-1515.
16. Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4inhibitors and lipids: systematic review and meta-analysis. Adv Ther. 2012;29(1): 14-25.
17. Gin H, Roudaut MF, Vergnot V, Baillet L, Rigalleau V. Effect of metformin on fibrinolytic parameters in insulin-treated, type 2 diabetic patients. Diabetes Metab. 2003;29(5):505-508.
18. Vilsbøll T, Rosenstock J, Yki-Järvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(2):167-177.
19. Bosi E. Time for testing incretin therapies in early type 1 diabetes? J Clin Endocrinol Metab. 2010;95(6):2607-2609.
20. Rother KI, Spain LM, Wesley RA, et al. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care. 2009;32(12):2251-2257.
21. Foley JE, Ligueros-Saylan M, He YL, et al. Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes. Horm Metab Res. 2008;40(10):727-730.
22. Boschmann M, Engeli S, Dobberstein K, et al. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab. 2009;94(3):846-852.
23. Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia. 2010;53(5):809-820.
24. Khan AS, McLoughney CR, Ahmed AB. The effect of metformin on blood glucose control in overweight patients with type 1 diabetes. Diabet Med. 2006;23(10):1079-1084.
25. Lund SS, Tarnow L, Astrup AS, et al. Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. Diabetes Obes Metab. 2009;11(10):966-977.
26. True MW. Circulating biomarkers of glycemia in diabetes management and implications for personalized medicine. J Diabetes Sci Technol. 2009;3(4):743-747.
27. Cohen RM, Holmes YR, Chenier TC, Joiner CH. Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy. Diabetes Care. 2003;26(1):163-167.